Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company based in Austin, Texas, specializing in the development of human enzyme therapeutics for rare genetic and cancer-related diseases. Founded in 2013, the company is focused on addressing unmet medical needs through innovative enzyme therapies. Its lead product candidate, pegzilarginase, is a recombinant human Arginase 1 enzyme currently undergoing a Phase III trial to assess its safety and efficacy in treating Arginase 1 deficiency. Additionally, Aeglea has a preclinical pipeline that includes several candidates targeting various metabolic disorders, such as ACN00177 for homocystinuria, AEB5100 for the degradation of plasma cystine and cysteine, and AEB2109, which focuses on methionine degradation. Aeglea BioTherapeutics aims to make significant advancements in the treatment of rare metabolic diseases through its specialized enzyme therapies.
Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). This chronic condition, which encompasses disorders such as ulcerative colitis and Crohn's disease, involves inflammation in the gastrointestinal tract. Spyre Therapeutics combines advanced antibody engineering with rational therapeutic combinations and precision medicine strategies to enhance patient selection. The company's goal is to create next-generation products that improve upon existing treatment options, which include anti-inflammatory drugs, immunosuppressants, and biologics. Through its robust pipeline, Spyre Therapeutics seeks to address the unmet needs of patients suffering from IBD.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.